Aadi bioscience announces $72.5 million private placement equity financing

Los angeles , sept. 22, 2022 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock ("common stock") at a price of $12.50 per share, reflecting the closing price on september 21, 2022 on nasdaq, and pre-funded warrants ("pre-funded warrants") to purchase up to an aggregate of 2,426,493 shares of common stock at a purchase price of $12.4999 per pre-funded warrant share, through a private investment in public equity ("pipe") financing.
AADI Ratings Summary
AADI Quant Ranking